Technical Analysis for BDSX - Biodesix, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Historical BDSX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Weak + Overbought | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | -5.73% | |
| Calm After Storm | Range Contraction | -5.73% | |
| Narrow Range Bar | Range Contraction | -5.73% | |
| NR7 | Range Contraction | -5.73% | |
| NR7-2 | Range Contraction | -5.73% | |
| Weak + Overbought | Other | -5.73% | |
| Inside Day | Range Contraction | -5.73% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 5% | 2 days ago | |
| 60 Minute Opening Range Breakdown | 2 days ago | |
| Down 3% | 2 days ago | |
| Down 2 % | 2 days ago | |
| Fell Below Previous Day's Low | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Diagnostics & Research
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.
Biopharmaceutical Lung Cancer
Biopharmaceutical Lung Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.13 |
| 52 Week Low | 10.85 |
| Average Volume | 321,148 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 14.20 |
| 10-Day Moving Average | 16.07 |
| Average True Range | 1.74 |
| ADX | 0.0 |
| +DI | 25.53 |
| -DI | 11.76 |
| Chandelier Exit (Long, 3 ATRs ) | 13.92 |
| Chandelier Exit (Short, 3 ATRs ) | 16.06 |
| Upper Bollinger Band | 19.06 |
| Lower Bollinger Band | 9.34 |
| Percent B (%b) | 0.78 |
| BandWidth | 68.50 |
| MACD Line | 1.83 |
| MACD Signal Line | 1.16 |
| MACD Histogram | 0.6696 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.37 | ||||
| Resistance 3 (R3) | 19.56 | 18.95 | 18.97 | ||
| Resistance 2 (R2) | 18.95 | 18.33 | 18.85 | 18.83 | |
| Resistance 1 (R1) | 17.94 | 17.95 | 17.64 | 17.75 | 18.70 |
| Pivot Point | 17.33 | 17.33 | 17.17 | 17.23 | 17.33 |
| Support 1 (S1) | 16.32 | 16.71 | 16.01 | 16.13 | 15.18 |
| Support 2 (S2) | 15.71 | 16.32 | 15.61 | 15.05 | |
| Support 3 (S3) | 14.70 | 15.71 | 14.91 | ||
| Support 4 (S4) | 14.51 |
